129 related articles for article (PubMed ID: 24637549)
21. Rapamycin ameliorates inflammation and fibrosis in the early phase of cirrhotic portal hypertension in rats through inhibition of mTORC1 but not mTORC2.
Wang W; Yan J; Wang H; Shi M; Zhang M; Yang W; Peng C; Li H
PLoS One; 2014; 9(1):e83908. PubMed ID: 24404143
[TBL] [Abstract][Full Text] [Related]
22. TORC1 signaling inhibition by rapamycin and caffeine affect lifespan, global gene expression, and cell proliferation of fission yeast.
Rallis C; Codlin S; Bähler J
Aging Cell; 2013 Aug; 12(4):563-73. PubMed ID: 23551936
[TBL] [Abstract][Full Text] [Related]
23. Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment.
Cao J; Huang W
PLoS One; 2016; 11(2):e0149388. PubMed ID: 26872016
[TBL] [Abstract][Full Text] [Related]
24. Potent dual inhibitors of TORC1 and TORC2 complexes (KU-0063794 and KU-0068650) demonstrate in vitro and ex vivo anti-keloid scar activity.
Syed F; Sanganee HJ; Singh S; Bahl A; Bayat A
J Invest Dermatol; 2013 May; 133(5):1340-50. PubMed ID: 23303455
[TBL] [Abstract][Full Text] [Related]
25. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
Guichard SM; Curwen J; Bihani T; D'Cruz CM; Yates JW; Grondine M; Howard Z; Davies BR; Bigley G; Klinowska T; Pike KG; Pass M; Chresta CM; Polanska UM; McEwen R; Delpuech O; Green S; Cosulich SC
Mol Cancer Ther; 2015 Nov; 14(11):2508-18. PubMed ID: 26358751
[TBL] [Abstract][Full Text] [Related]
26. Effective targeting of colorectal cancer cells using TORC1/2 kinase inhibitors in vitro and in vivo.
Zhang J; Jiang W; Liu W; Wu JJ; Song L; Cheng JX; Yao M; Yang LP; Yao DF
Future Oncol; 2016 Feb; 12(4):515-24. PubMed ID: 26776341
[TBL] [Abstract][Full Text] [Related]
27. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
Wang X; Lai P; Zhang Z; Huang M; Wang L; Yin M; Jin D; Zhou R; Bai X
Oncol Rep; 2014 Jul; 32(1):382-8. PubMed ID: 24840134
[TBL] [Abstract][Full Text] [Related]
28. The Enigma of Rapamycin Dosage.
Mukhopadhyay S; Frias MA; Chatterjee A; Yellen P; Foster DA
Mol Cancer Ther; 2016 Mar; 15(3):347-53. PubMed ID: 26916116
[TBL] [Abstract][Full Text] [Related]
29. mTORC1 inhibitors rapamycin and metformin affect cardiovascular markers differentially in ZDF rats.
Nistala R; Raja A; Pulakat L
Can J Physiol Pharmacol; 2017 Mar; 95(3):281-287. PubMed ID: 28177677
[TBL] [Abstract][Full Text] [Related]
30. Effect of mTORC1/mTORC2 inhibition on T cell function: potential role in graft-versus-host disease control.
Herrero-Sánchez MC; Rodríguez-Serrano C; Almeida J; San-Segundo L; Inogés S; Santos-Briz Á; García-Briñón J; SanMiguel JF; Del Cañizo C; Blanco B
Br J Haematol; 2016 Jun; 173(5):754-68. PubMed ID: 26914848
[TBL] [Abstract][Full Text] [Related]
31. TORC2 Structure and Function.
Gaubitz C; Prouteau M; Kusmider B; Loewith R
Trends Biochem Sci; 2016 Jun; 41(6):532-545. PubMed ID: 27161823
[TBL] [Abstract][Full Text] [Related]
32. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro.
Li Q; Song XM; Ji YY; Jiang H; Xu LG
Biochem Biophys Res Commun; 2013 Nov; 440(4):701-6. PubMed ID: 24103749
[TBL] [Abstract][Full Text] [Related]
33. mTORC1 inhibition in the nucleus accumbens 'protects' against the expression of drug seeking and 'relapse' and is associated with reductions in GluA1 AMPAR and CAMKIIα levels.
James MH; Quinn RK; Ong LK; Levi EM; Charnley JL; Smith DW; Dickson PW; Dayas CV
Neuropsychopharmacology; 2014 Jun; 39(7):1694-702. PubMed ID: 24469593
[TBL] [Abstract][Full Text] [Related]
34. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.
Zhang X; Wang X; Qin L; Xu T; Zhu Z; Zhong S; Zhang M; Shen Z
Urology; 2015 Jan; 85(1):273.e1-7. PubMed ID: 25440763
[TBL] [Abstract][Full Text] [Related]
35. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
36. The Ups and Downs of TORKinibs in Transplantation.
Fantus D; Thomson AW
Transplantation; 2015 Aug; 99(8):e117-8. PubMed ID: 26308303
[No Abstract] [Full Text] [Related]
37. Current development of the second generation of mTOR inhibitors as anticancer agents.
Zhou HY; Huang SL
Chin J Cancer; 2012 Jan; 31(1):8-18. PubMed ID: 22059905
[TBL] [Abstract][Full Text] [Related]
38. Circadian protein affects mTORC1 activity.
Greenhill C
Nat Rev Endocrinol; 2019 Feb; 15(2):65. PubMed ID: 30542149
[No Abstract] [Full Text] [Related]
39. Phenotypes associated with inherited and developmental somatic mutations in genes encoding mTOR pathway components.
Saxena A; Sampson JR
Semin Cell Dev Biol; 2014 Dec; 36():140-6. PubMed ID: 25263008
[TBL] [Abstract][Full Text] [Related]
40. Inactivation of Regulatory-associated Protein of mTOR (Raptor)/Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in Osteoclasts Increases Bone Mass by Inhibiting Osteoclast Differentiation in Mice.
Dai Q; Xie F; Han Y; Ma X; Zhou S; Jiang L; Zou W; Wang J
J Biol Chem; 2017 Jan; 292(1):196-204. PubMed ID: 27879318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
